Cellectar Biosciences (Cellectar Biosciences) Buildings And Improvements

: $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

Cellectar Biosciences's quarterly buildings and improvements declined from Jun. 2023 ($0.53 Mil) to Sep. 2023 ($0.52 Mil) and declined from Sep. 2023 ($0.52 Mil) to Dec. 2023 ($0.00 Mil).

Cellectar Biosciences's annual buildings and improvements increased from Dec. 2021 ($0.21 Mil) to Dec. 2022 ($0.56 Mil) but then declined from Dec. 2022 ($0.56 Mil) to Dec. 2023 ($0.00 Mil).

Cellectar Biosciences Buildings And Improvements Historical Data

The historical data trend for Cellectar Biosciences's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectar Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Buildings And Improvements

0.35

0.28

0.21

0.56

Cellectar Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Buildings And Improvements																0.56	0.55	0.53	0.52	-

Cellectar Biosciences Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Cellectar Biosciences (Cellectar Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectar Biosciences Inc (NAS:CLRB) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

NV4:Germany NV4:Germany

Address

100 Campus Drive, Florham Park, NJ, USA, 07932

Website

https://www.cellectar.com

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.

Executives

Andrei Shustov	officer: Senior Vice President, Medical	7 PARKLAND DRIVE, MILFORD NJ 08848
Darrell Shane Lea	officer: Chief Commercial Officer	7 PARKLAND DRIVE, MILFORD NJ 08848
Chad J Kolean	officer: Chief Financial Officer	C/O CELLECTAR BIOSCIENCES, INC., 3301 AGRICULTURE DRIVE, MADISON WI 53716
Douglas J Swirsky	director	C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Frederick W Driscoll	director
Asher Chanan-khan	director	C/O CELLECTAR BISCIENCES, INC., 100 CAMPUS DRIVE NJ 07932
James V Caruso	director, officer: President and CEO	C/O CELLECTAR BIOSCIENCES, INC., 8383 GREENWAY BLVD STE 600, MIDDLETON WI 53562
Dov Elefant	officer: Chief Financial Officer	EPICEPT CORPORATION, 270 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Jarrod Longcor	officer: Chief Business Officer	C/O RIB-X PHARMACEUTICALS, INC., 300 GEORGE STREET, SUITE 301, NEW HAVEN CT 06511
Friend John E. Ii	officer: VP, Chief Medical Officer	26 ORCHARD LANE, COLT NECK NJ 07722
John Neis	director	505 S. ROSA ROAD, SUITE 201, MADISON WI 53719
Stefan Loren	director	3226 AVENIDA DE SUENO, CARLSBAD CA 92009
Stephen A Hill	director	50 AVENUE GENERAL DE GAULLE, BRUXELLES C9 9999999999
Igor D Grachev	officer: Chief Medical Officer	15 REID LANE, MILLSTONE TWP NJ 08535
Bernhardt Charles Thomas Iii	officer: Interim CFO	23 BIRCH ROAD, MALVERN PA 19355